Some authors have suggested possible benefit from immunotherapy basing on the expression in the microenvironments of PCs of lymphocytes infiltrating the tumor, death ligand 1 and CD68+ as potential biomarkers target in cancer therapies [106]. This evidence concerns the gene CD68 and cancer.